Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
Exact Sciences Stockholders Approve Acquisition by Abbott
20.02.2026 21:05
MADISON, Wis., February 20, 2026--Exact Sciences Corporation (NASDAQ: EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today.
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
20.02.2026 20:13
Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 6, Abbott Laboratories (NYSE:ABT) released positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) occluder, presented at the AF Symposium in Boston. Atrial fibrillation is an irregular heart rhythm disease that affects millions of […]
Abbott declares 409th consecutive quarterly dividend
20.02.2026 16:38
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
20.02.2026 14:27
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
Pivot Bio to Present at Bank of America 2026 Global Agriculture and Materials Conference
20.02.2026 13:20
MINNEAPOLIS, February 20, 2026--Pivot Bio, one of the world's leading innovative agtech companies, will attend the Bank of America 2026 Global Agriculture and Materials Conference on February 25-26, 2026.
SENS Eversense 365 Integrated With twiist Gains Full Availability
20.02.2026 12:15
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
Senseonics launches automated insulin dosing system with 1-year CGM
20.02.2026 10:00
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
Weight Management Supplements Market Report 2026: A $15+ Billion Market by 2030 Featuring Leading Players - Nestle, Abbott Laboratories, GSK, Glanbia, Herbalife Nutrition, and Amway - Forecast to 2035
20.02.2026 09:18
Key market opportunities include rising demand for personalized nutrition solutions, growth of plant-based supplements, and increased online sales of weight management products. The industry is also driven by trends like clean-label ingredients, regional expansions, and the integration of digital health platforms. Weight Management Supplements Market Weight Management Supplements Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Weight Management Supplements Market Report 2026" has been adde
Bionic Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts to 2033
18.02.2026 16:13
The global Bionic Devices Market is projected to surge to approximately USD 11.90 billion by 2033, from USD 6.22 billion in 2025, at a CAGR of 8.45%. Key growth drivers include technological advancements in wearable robotics, rising demand for non-invasive treatments, and increasing chronic illnesses. AI innovations and healthcare spending further enhance bionic devices' performance. Leading companies in this field, such as Abbott Laboratories, Abiomed, and Edwards Lifesciences, are driving glob
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
18.02.2026 14:00
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS)
18.02.2026 01:08
Exact Sciences’ story has shifted toward the US$105 per share Abbott offer becoming the key anchor for what many investors watch as a reference value, and that is now reflected in a fair value estimate that holds steady at US$105.81 per share. Behind that headline number, the discount rate has nudged slightly lower from 7.25% to 7.24% and revenue growth assumptions have moved from 12.30% to 11.03%, as analysts increasingly frame their models around the agreed deal price rather than longer...
RFK Jr.’s Next Overhaul: America’s Baby Formula Guidelines
17.02.2026 02:00
The administration is expected to begin unveiling “Operation Stork Speed” this spring but is unlikely to act on calls to remove seed oils from infant formula.
Could The Market Be Wrong About Abbott Laboratories (NYSE:ABT) Given Its Attractive Financial Prospects?
15.02.2026 11:00
Abbott Laboratories (NYSE:ABT) has had a rough three months with its share price down 13%. However, stock prices are...
Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer
13.02.2026 11:15
If you are wondering whether Exact Sciences at around US$103 a share still offers value, you are not alone. This article is all about putting that price tag into context. The stock has returned 0.6% over the last 7 days, 1.0% over 30 days, 1.5% year to date and 104.1% over the past year, while the 3 year return sits at 61.9% and the 5 year return at a 27.1% decline. Recently, headlines have focused on Exact Sciences as a key player in cancer screening and diagnostics, with media coverage...
Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)
11.02.2026 11:01
Key Insights The projected fair value for Abbott Laboratories is US$95.90 based on 2 Stage Free Cash Flow to Equity...
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating
08.02.2026 09:27
Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data […]
Insider Stock Buying Reaches US$3.10m On Abbott Laboratories
07.02.2026 11:00
Over the last year, a good number of insiders have significantly increased their holdings in Abbott Laboratories...
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
06.02.2026 13:00
Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Pos
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
05.02.2026 12:00
ACTON, Mass., February 05, 2026--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions
03.02.2026 17:02
Medical device leaders counter tariff pressures with innovation, as AI adoption and aging demographics support long-term growth.